<DOC>
	<DOCNO>NCT01217749</DOCNO>
	<brief_summary>The purpose study determine efficacy safety fixed-dose , daily regimen orally administer PCI-32765 combined ofatumumab subject relapsed/refractory CLL/SLL related disease</brief_summary>
	<brief_title>Efficacy Safety Study PCI-32765 Combine With Ofatumumab CLL</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Subjects histologically confirm chronic lymphocytic leukemia ( CLL ) , small lymphocytic lymphoma ( SLL ) , prolymphocytic leukemia ( PLL ) , Richter 's transformation arise CLL/SLL define WHO classification hematopoietic neoplasm satisfy ≥ 1 follow condition : Progressive splenomegaly and/or lymphadenopathy identify physical examination radiographic study Anemia ( &lt; 11 g/dL ) thrombocytopenia ( &lt; 100,000/μL ) due bone marrow involvement Presence unintentional weight loss &gt; 10 % precede 6 month NCI CTCAE Grade 2 3 fatigue Fevers &gt; 100.5 degree night sweat &gt; 2 week without evidence infection Progressive lymphocytosis increase &gt; 50 % 2 month period anticipate doubling time &lt; 6 month Need cytoreduction prior stem cell transplant 2 . Subjects must fail ≥ 2 prior therapy CLL include nucleoside analog ≥ 2 prior therapy include nucleoside analog contraindication therapy 3 . 10 % expression CD20 CLL/SLL cell 4 . ECOG performance status ≤ 2 5 . Life expectancy ≥ 12 week 6 . Subjects must organ marrow function define : Absolute neutrophil count ( ANC ) ≥ 1000/µL absence bone marrow involvement Platelets ≥ 30,000/μL absence bone marrow involvement Total bilirubin ≤ 1.5 x institutional upper limit normal unless due Gilbert 's disease AST ( SGOT ) ≤ 2.5 x institutional upper limit normal unless due infiltration liver Creatinine ≤ 2.0 mg/dL OR creatinine clearance ≥ 50 mL/min 7 . No history prior exposure ofatumumab 8 . Age ≥ 18 year 9 . Body weight ≥ 40 kg 1 . A lifethreatening illness , medical condition organ system dysfunction , investigator 's opinion , could compromise subject 's safety , interfere absorption metabolism PCI32765 PO , put study outcome undue risk 2 . Significant cardiovascular disease 3 . Any condition could interfere absorption metabolism PCI32765 include unable swallow capsule , malabsorption syndrome , disease significantly affect gastrointestinal function , resection stomach small bowel ulcerative colitis , symptomatic inflammatory bowel disease , partial complete bowel obstruction 4 . Known history Human Immunodeficiency Virus ( HIV ) active infection Hepatitis C Virus ( HCV ) Hepatitis B Virus ( HBV ) uncontrolled active systemic infection 5 . Any anticancer immunotherapy , chemotherapy , radiotherapy , experimental therapy within 4 week first dose study drug . Corticosteroids diseaserelated symptom allow provide 1 week washout occur 6 . Active central nervous system ( CNS ) involvement lymphoma 7 . Major surgery within 4 week first dose study drug 8 . Lactating pregnant 9 . Known moderate severe chronic obstructive pulmonary disease ( COPD ) 10 . History prior malignancy , except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , cancer subject disease free least 2 year limit survival &lt; 2 year 11 . History Grade ≥ 2 toxicity continue prior anticancer therapy include radiation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>